All In Biotech

Drug Trial Radar · NCT05059951

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15,000

Planned (sponsor's estimate)

Start

Oct 3, 2021

Primary completion

Sep 15, 2026

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 28, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • Immune checkpoint inhibitorDrug

    Chemotherapy follow the guild line.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.